2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Molecular Testing, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Non-Biological Therapies, Chemotherapy, Adverse Events, Biological Processes, Genomics, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Quality Improvement, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, Translational Research, CML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult
PAPER

1991 Global burden of chronic myeloid leukemia and attributable risk factors in 204 countries and territories, from 1990 to 2021: Results from the global burden of disease study 2021

Yue Zhou, PhD, Qian Jiang Jr, MD2, Xiaojun Huang, MD,PhD3, Shengye Lu, MD4
1 Peking University People's Hospital, Beijing, Beijing, China
2 Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China, National Clinical Research Center for Hematologic Disease, Beijing, China, Peking University Institute of Hematology, Beijing, China, Peking University People's Hospital, Beijing, Beijing, China
3 Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China, National Clinical Research Center for Hematologic Disease, Beijing, China, Peking University Institute of Hematology, Beijing, China, Peking University People's Hospital, Beijing, Beijing, China, Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Beijing, China, State Key Laboratory of Natural and Biomimetic Drugs, Beijing, China
4 Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China, National Clinical Research Center for Hematologic Disease, Beijing, China, Peking University Institute of Hematology, Beijing, China, Peking University People's Hospital, Beijing, Beijing, China, Peking University People’s Hospital Medical Information Center, Beijing, China

Introduction:

Chronic myeloid leukemia (CML) imposes substantial global health impact. While tyrosine kinase inhibitors (TKIs) have transformed CML management in high-income settings, up-to-date assessments of the global burden and its drivers remain lacking. We aimed to characterize the temporal trends, geographic disparities, and attributable risk factors of CML incidence, mortality, and disability-adjusted life-years (DALYs) from 1990 to 2021.

Methods:

We extracted annual estimates for CML incidence, deaths, and DALYs from the Global Burden of Disease (GBD) 2021 database including 204 countries and territories from 1990 to 2021. Age-standardized rates (ASR) per 100,000 and estimated annual percentage changes (EAPC) were calculated to quantify trends over past 31 years. Countries were stratified by the sociodemographic index (SDI) into five levels. Attributable risk factors from high body-mass index (HBMI), tobacco, and occupational exposures were analyzed regionally.

Results:

Globally, CML incident cases decreased from 39,500 in 1990 to 35,800 in 2021, with the age-standardized incidence rate (ASIR) declining from 0.9 to 0.4 per 100,000 (EAPC: -3.0; 95% CI: [-3.2, -2.8]). The high SDI region showed the steepest decline (EAPC: -3.8 [-4.1, -3.5]). A strong positive correlation was observed between SDI and ASIR (R=0.818, p<0.001). CML deaths fell globally (EAPC: -3.4 [-3.6, -3.3]), with the age-standardized death rate (ASDR) reaching 0.3 per 100,000 in 2021; the high SDI region again led reductions (EAPC: -5.0 [-5.3, -4.7]). DALYs declined from 1990 to 2021 (EAPC: -3.6 [-3.8, -3.5]), yet the middle SDI region bore the highest absolute burden. Males experienced higher incidence, mortality, and DALYs than females across all regions. Globally, CML death rates rose with age and peaked among those aged over 95, a pattern consistent across all SDI regions. All age groups saw mortality declines relative to 1990, with the most marked reductions in the 80–84 and 85–89 age groups in high-SDI regions. DALY rates followed comparable trends, increasing with age and reaching the maximum in the 90–94 age group; high-SDI regions achieved the largest DALY rate reductions during the study period, whereas trends in less developed regions, particularly low-middle and low-SDI regions, remained relatively stable versus 1990. Regarding risk factors, tobacco remained the leading contributor to CML deaths globally and in several high-burden regions, while as the predominant attributable factor in most other regions and its contribution increased from 7.1% in 1990 to 8.8% in 2021. 

Conclusions:

Over three decades, the global CML burden has declined markedly, mainly due to advanced therapy and molecular diagnostic techniques, occupational hazard controls and tobacco mitigation in high-SDI areas. However, the geographic and socioeconomic gaps persist: certain low-SDI countries face rising CML incidence, and restricted targeted therapy access slows mortality reduction there. The growing contribution of HBMI to CML burden indicates a new modifiable public health target. These population-based epidemiologic results support strategies to expand equitable TKI access, enhance cancer surveillance, and implement metabolic risk interventions to eliminate worldwide disparities in CML care.

Yue Zhou, PhD: No relevant conflicts of interest to declare.